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What is known on this topic What this paper adds 
• COPD is association with venous 
thromboembolism (VTE) and mortality. 
• COPD is associated with an inactive life-
style, and physical inactivity is 
associated with increased mortality 
• In VTE patients, severe COPD is 
associated with an increased risk of 
death 
• The increased risk of death in VTE 
patients with severe COPD was not 





Background: Previous studies have shown increased mortality in venous thromboembolism (VTE) 
patients with chronic obstructive pulmonary disease (COPD), but it is unknown to what extent the 
association is influenced by the severity of COPD and physical inactivity. 
Objectives: To investigate whether COPD, and stages of COPD, influenced the risk of mortality after a 
first episode of VTE when physical inactivity was taken into account.  
Methods: Patients with a first lifetime VTE (n=256) were recruited among individuals who 
participated and performed spirometry in the fifth (2001-02) and sixth (2007-08) surveys of the 
Tromsø Study (n=9577). All-cause mortality was registered up to December 31, 2015. 
Results: There were 123 deaths during a median of 2.9 years of follow-up. The overall mortality rate 
was 11.9 (95% CI 10.0-14.2) per 100 person-years. The risk of death was 2-fold higher in COPD 
patients compared to those with normal airflow (HR 2.00, 95% CI 1.30-3.08) after multivariable 
adjustment. The risk of death increased with the severity of COPD. VTE patients with COPD stage 
III/IV had a 5-fold increased risk of death (HR 5.20, 95% CI 2.65-10.2) compared to those without 
COPD, and 50% of these patients died within 3.5 months after the incident VTE event. Adjustment for 
physical inactivity had minor effect on the risk estimates.   
Conclusions: VTE patients with COPD had increased risk of death, particularly patients with severe 
COPD. The detrimental effect of COPD on mortality in VTE patients was apparently explained by 





Venous thromboembolism (VTE), a collective term for deep vein thrombosis (DVT) and pulmonary 
embolism (PE), is a common disease with serious short- and long-term complications (1-3).  The 30-
day case-fatality rate after a first VTE is reported to be 5-10% (4-6), and the overall 1-year mortality 
rate is around 20-25% (4-6). In patients with PE, the most common cause of early mortality is related 
to the PE itself (7). In the absence of recurrent VTE, long-term mortality is often attributed to 
comorbid conditions rather than to the VTE itself (8). Identification of subjects with high mortality 
risk is of importance for risk stratification and management of VTE patients.    
Chronic obstructive pulmonary disease (COPD) is a public health concern due to frequent 
hospitalizations, severe co-morbidities, and a high mortality rate (9, 10). Among patients hospitalized 
for acute COPD-exacerbation, 5-10% die during hospitalization and 20% die during the first year after 
hospital discharge (11, 12). Results from registry-based studies and cohorts have shown that COPD is 
associated with a 2- to 5-fold increased risk of VTE (13-16), and the prevalence of acute PE is high 
(15-30%) in COPD patients hospitalized with suspected acute exacerbation (13, 17, 18). A 
concomitant VTE is associated with prolonged hospital stay and higher 1-year mortality in COPD 
patients (19).  
Few studies have investigated the impact of concurrent respiratory disease on mortality risk 
in patients with VTE. A 1.4 to 2.2-fold higher risk of mortality has been reported in VTE patients (20, 
21) and PE patients (22) with concurrent COPD compared to those without COPD. However, in these 
studies, information on the COPD diagnosis was abstracted from the medical records (20-23) without 
differentiating between stages of COPD. In addition, these studies did not take into account that 
COPD, and particularly severe COPD, is associated with an inactive lifestyle (24, 25) which has a 
detrimental influence on mortality risk (21, 26, 27). Consequently, it was not possible to draw 
conclusions about the risk of death according to the severity of COPD in VTE patients, and to 
determine to what extent the increased mortality in COPD patients with VTE was explained by 
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physical inactivity. Therefore, we aimed to investigate whether severity of COPD influenced mortality 




Study population  
Patients with a first lifetime VTE (n=256) were recruited among participants in the fifth (2001-02) and 
sixth (2007-08) surveys of the Tromsø Study (28), a cohort of individuals derived from the general 
population of Tromsø municipality in Norway, during the period 2001-2015 (n=9577). The medical 
record for each potential case of VTE was reviewed by trained personnel, and a VTE was considered 
verified when presence of clinical signs and symptoms of DVT or PE were combined with objective 
confirmation tests (compression ultrasonography, venography, spiral computed tomography, 
perfusion-ventilation scan, pulmonary angiography, or autopsy), and resulted in a VTE diagnosis that 
required treatment, as previously described in detail (29). VTE cases derived from the autopsy 
registry were recorded when the death certificate indicated VTE as cause of death or as a significant 
condition associated with death. The study was approved by the regional committee for health and 
research ethics, and all participants gave their informed written consent. 
 
Assessment and classification of chronic obstructive pulmonary disease (COPD) 
Spirometry was assessed at enrolment in the Tromsø study, as previously described in detail (16). 
The American Lung Association criteria for spirometry testing were followed (30). Current drug 
therapy was not interrupted before the test. Reversibility test was not performed. Predicted values 
of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio were 
calculated according to Langhammer et al. (31). Spirometry was accepted in subjects who expired for 
more than 3 seconds. To avoid misclassification of healthy subjects as obstructive, those with 
FEV1/FVC <0.7 or predicted FEV1 <80% were excluded from the analyses if peak expiratory flow (PEF) 
was below 3 x forced expiratory flow when 75% of the air had been expired (PEF >3 x FEF75) (32). 
6 
 
The subjects were allocated into four groups based on lung function according to the Global Initiative 
of Chronic Obstructive Lung Disease (GOLD) guidelines (33). Due to few subjects with severe 
obstruction, participants with COPD stages III and IV (predicted FEV1 <50% combined with a 
FEV1/FVC ratio <0.7) were merged into one category for the analyses.  
 
Other measurements 
Height and weight were measured at enrolment in the Tromsø study with subjects wearing light 
clothes and no shoes. Body mass index (BMI) was calculated as weight in kilograms divided by the 
square of height in meters (kg/m2). Information on smoking status (current, former, never), physical 
activity, dyspnea (when walking calmly, washing/dressing or at rest), daily cough and history of 
cardiovascular disease (myocardial infarction, stroke or angina pectoris) was collected from a self-
administered questionnaire.  We classified subjects as inactive (i.e. ‘no activity’ or ‘< 1 h per week) or 
active (i.e. ‘≥ 1 h per week’) based on their reported weekly amount of light and hard physical 
activity, as previously described in detail (34). Information on active cancer at the time of the VTE, 
and acute medical conditions (including myocardial infarction, stroke, and acute infections) in the 
three months preceding the VTE, was extracted by thorough review of medical records using a 
standardized form.  
 
Outcomes 
Death from any cause was the primary outcome, and information on all-cause mortality was 
obtained from the National Population Registry of Norway. 
 
Statistical analyses 
For each individual, person-time of follow up was accrued from the date of the first VTE to the date 
of death or study end (December 31, 2015). Mortality rates (MR) were calculated and expressed as 
number of deaths per 100 person-years. A Kaplan Meier plot was made to display the ten-year 
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survival after VTE according to stages of COPD. Cox-regression models were used to estimate hazard 
ratios (HR) with 95% confidence interval (CI) for all-cause mortality according to stages of COPD. 
Analyses were conducted for overall VTE and in subgroups according to clinical presentation (i.e. PE 
and DVT). In order to adjust for age and sex, age was used as time-scale and sex was included as a co-
variate in the regression model. In a second adjustment model, physical activity was added, and in a 
third adjustment model, we adjusted for age (time scale), sex, physical activity, BMI, smoking status, 
active cancer, history of cardiovascular diseases, and acute medical conditions. The proportional 




Among the 256 subjects with VTE, 161 (62.9%) had normal airflow, 35 (13.7%) had COPD stage I, 44 
(17.1%) had COPD stage II and 16 (6.3%) had COPD stages III/IV (Table 1). Patients with COPD stage 
III/IV were older (mean age 76.3 versus 73.1 years) and had lower BMI (25.8 versus 28.7 kg/m2) 
compared with those with normal airflow. Moreover, the proportions of current smokers (56.3% 
versus 12.5%) and patients with active cancer (43.8% versus 31.1%) were higher among those with 
COPD stage III/IV. 
The median follow-up time after VTE was 2.9 years (range 1 day to 13.9 years). During follow-
up, 123 patients died, yielding an overall mortality rate of 11.9 (95% CI: 10.0-14.2) per 100 person-
years. The risk of death was 2-fold higher in COPD patients than in those with normal airflow (HR 
1.97, 95% CI: 1.36-2.84) (Table 2). Adjustment for physical activity did not alter the risk estimates, 
and neither did further adjustments for BMI, smoking, cancer, history of cardiovascular disease and 
acute medical conditions.  
Patients with COPD stage III/IV had significantly poorer survival after a VTE than those with 
normal airflow (Figure 1), and 50% of the patients with COPD stage III/IV died within the first 3.5 
months. The crude mortality rate increased across stages of COPD from 9.4 per 100 person-years in 
those with stage I, to 50.7 per 100 person-years in those with stage III/IV (Table 3). The risk of death 
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was more than 5-fold higher in those with COPD stage III/IV (HR 5.97, 95% CI: 3.29-10.8), compared 
with those with normal airflow. In those with an initial PE, the relative risk of death was even higher, 
and patients with COPD stage III/IV had a 7-fold higher risk of death compared with those with 
normal airflow (HR 7.48, 95% CI: 3.07-18.2). Adjustment for BMI, physical activity, smoking status, 
cancer, history of cardiovascular disease and acute medical conditions did not alter the risk estimates 
(Table 3). 
Among the VTE patients with severe COPD (stage III/IV), 43.8% had cancer. When we 
restricted our analyses to patients without active cancer (Supplementary table 1), the HR for death in 
those with stage III/IV versus normal was 11.4 (95 % CI: 3.4-38.2). The corresponding HR among 
those with cancer was 4.67 (1.45-15.0). However, the overall number of events in each strata (i.e. 
with and without cancer) were small, and these estimates should be interpreted with caution. 
 
Discussion 
In the present study, we investigated whether COPD, assessed by spirometry, influenced the risk of 
all-cause mortality in patients with VTE. We found that, VTE patients with concomitant COPD had a 
2-fold higher risk of death compared to patients without COPD. The crude mortality rates and 
relative risks of mortality in VTE patients increased with the severity of COPD.  In patients with PE, 
those with COPD stage III/IV had a 7.3-fold higher risk of death compared to those without COPD. 
Correspondingly, in DVT patients, the risk of death was 3.8-fold higher in those with COPD stage 
III/IV. Overall, 50% of the VTE patients with COPD stage III/IV died within the initial 3.5 months. 
Although the proportion of inactive subjects increased with the severity of COPD, inactivity did not 
explain the increased mortality in COPD patients. Further, the higher death rate in VTE patients with 
severe COPD could not be explained by concomitant cancer or history of cardiovascular diseases, as 
the results remained essentially unchanged when these comorbidities were adjusted for in the 
multivariable model. Our findings suggest that particular attention and medical care should be 
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brought to VTE patients with concomitant COPD, and severe COPD in particular, to prevent the high 
short-term risk of death in these patients.   
In coherence with previous studies, we found that VTE patients with concomitant COPD had 
an almost 2-fold higher mortality risk than those without COPD.  In a cohort of 399 PE patients, of 
whom 95 died within a year, the presence of chronic lung disease (defined by a history of COPD, 
interstitial lung disease or pulmonary fibrosis on chest radiography) was associated with a 2.2-fold 
increased risk of death (22). In a study of 2218 VTE cases occurring among Olmsted County residents 
in the period 1966-1990, chronic lung disease was associated with a 1.4-fold increased risk of both 
short-term and long-term mortality in multivariable analyses (20). Likewise, Piazza et al. reported 
that among 2488 VTE patients from the Worcester study, of whom 484 (19.5%) had a history of 
COPD, concomitant COPD was associated with a 2.0-fold increased risk of death within 30 days after 
the VTE diagnosis (21).  We extend these findings by showing that the impact of COPD on mortality in 
VTE patients increased with the severity of COPD. VTE patients with concomitant COPD stage III/IV 
had a 5.3-fold higher mortality risk than those without COPD with a particular steep mortality rate 
during the first months after VTE diagnosis. Our findings indicate that approximately 60% of VTE 
patients with concomitant COPD stage III/IV will die during the first year after the VTE diagnosis. 
Several mechanisms may underlie the observed impact of COPD on VTE-related mortality.  
First, COPD patients often suffer from multiple comorbid conditions (20-22), such as arterial 
cardiovascular diseases, infections and cancer, which may confound the apparent association 
between COPD and VTE-related mortality. Smoking is associated with both COPD and cancer (35, 36), 
and active cancer is associated with a 4 to 7-fold increased risk of VTE (37) and a substantial 
worsening of the VTE prognosis (5, 6). Similarly, COPD is associated with an increased risk of arterial 
cardiovascular diseases (38), and arterial cardiovascular diseases are associated with a transiently 
increased risk of VTE  (39, 40) and poor prognosis (41). Infection is known to be a provoking factor for 
VTE (42), and concomitant respiratory infection increases the mortality risk in COPD patients (43). 
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Moreover, COPD represents a chronic inflammatory state which may influence the risk of adverse 
outcome (44). In our study, the impact of COPD on VTE-related mortality was neither explained by 
concomitant cancer, infections, nor arterial cardiovascular diseases since the risk estimates of VTE-
related mortality remained essentially unchanged when active cancer, acute medical conditions and 
a history of MI and stroke were included in the adjustment models. Second, COPD, and particularly 
severe COPD, is associated with an inactive lifestyle (24, 25, 45) and frequent immobilization during 
hospitalization (21), which are both detrimental predictors of mortality (21, 26, 27). Even though 
physical inactivity was associated with increased mortality in the VTE patients, the impact of COPD 
on VTE-related death was not explained by inactivity since adjustment for inactivity had a minor 
effect on the risk estimates for death in COPD patients. Third, patients with COPD, of whom many 
have already developed chronic right ventricular dysfunction, are susceptible to cardiovascular 
collapse due to superimposed right ventricular failure following symptomatic and asymptomatic PE 
(46). Unfortunately, we did not have detailed information on heart failure, infections and degree of 
inflammation, and could therefore not take this into account in our analyses. Of note, the patients 
with severe COPD had lower BMI than those with normal airflow, a feature recognized in many 
studies as the “obesity paradox” (47). 
The main strengths of the study are the well-validated VTE events derived from a general 
population cohort, objective assessment of lung function, which allowed for categorization into 
stages of COPD, possibility to adjust for confounders, and the complete follow-up. Some limitations 
should also be addressed. The statistical power was somewhat limited in subgroup analysis due to 
few events, resulting in wide confidence intervals. Therefore, our results should be interpreted with 
caution. Moreover, COPD is a progressive disease, and the stages of COPD may have changed during 
follow-up leading to some degree of exposure misclassification. In addition, our spirometry measures 
were carried out without a test of reversibility, and some subjects with asthma could have been 
misclassified as having COPD. This potential misclassification would be non-differential, and most 
likely lead to an underestimation of the true association due to regression dilution bias.  
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Unfortunately, we did not have information on specific causes of death, and therefore we could not 
further disentangle the reasons for the increased mortality in VTE patients with COPD.  
In conclusion, COPD was associated with a higher risk of death in patients with a first VTE, 
and this was particularly pronounced among those with severe COPD. Physical inactivity could not 
explain the increased risk of mortality observed in VTE patients with COPD, indicating that 
mechanisms other than physical inactivity play a more important role in increasing the risk of death 
in VTE patients with COPD.  Our findings suggest that attention should be drawn to prevention and 
management of VTE, particularly in patients with severe COPD.  
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Figure 1: Survival after a first venous thromboembolism (VTE) according to stages of chronic 




Table 1. Characteristics of the VTE patients (n=256) across categories of COPD. 
 Normal COPD  Stage I 
COPD 
 Stage II 
COPD 
 Stage III/IV 
n 161 35 44 16 
Age, years 73.1 ± 9.2 75.2 ± 9.3 75.1 ± 7.0 76.3 ± 5.7 
Sex, % men 49.1 (79) 57.1 (20) 54.6 (24) 50.0 (8) 
Pulmonary embolism, % 50.3 (81) 60.0 (21) 45.5 (20) 50.0 (8) 
Deep vein thrombosis, % 49.7 (80) 40.0 (14) 54.5 (24) 50.0 (8) 
Unprovoked VTE 37.9 (61) 34.3 (12) 31.8 (14) 31.3 (5) 
BMI, kg/m2 28.7 ± 4.3 25.4 ± 3.4 26.3 ± 3.7 25.8 ± 5.3 
Current smoking, % 12.5 (20) 22.9 (8) 50.0 (22) 56.3 (9) 
Former smoking, % 47.5 (76) 57.1 (20) 40.9 (18) 31.3 (5) 
Physical Inactivity (%) 26.7 (43) 22.9 (8) 40.9 (18) 50.0 (8) 
Active Cancer, % 31.1  (50) 25.7 (9) 34.1 (15) 43.8 (7) 
Cardiovascular disease, % 19.3 (31) 17.1 (6) 27.3 (12) 25.0 (4) 
Acute medical conditions, % 12.4 (20) 25.7 (9) 9.1 (4) 18.8 (3) 
Dyspnea, % 6.8 (11) 14.3 (5) 13.6 (6) 31.3 (5) 
Cough daily, % 13.0 (21) 31.4 (11) 29.6 (13) 50.0 (8) 
FEV1, liters 2.6 ± 0.7 2.8 ± 0.7 1.9 ± 0.4 1.1 ± 0.3 
FVC, liters 3.5 ± 0.9 4.2 ± 1.1 3.0 ± 0.8 2.2 ± 0.7 
FEV1/FVC, % 75.5 ± 3.5 65.4 ± 3.6 62.4 ± 6.9 49.1 ± 9.1 
FEV1 % normal 92.0±15.0 94.1±11.3 66.7±8.6 40.3±7.8 
Physical inactivity: <1 hour of physical activity per week 
Cardiovascular disease: History of myocardial infarction, stroke or angina pectoris 
Acute medical conditions: acute myocardial infarction, stroke or major infectious disease within 8 weeks before 
the VTE. 
FEV1: forced expiratory volume in 1 second 




Table 2. Mortality rates (MR) and Hazard ratio (HR) with 95% confidence intervals (CI) of death in patients with a first venous thromboembolism (VTE) 
according to chronic obstructive pulmonary disease (COPD). 
 
 Person- years Deaths MR 
 (95% CI)a HR  (95% CI) b HR  (95% CI)c HR  (95% CI)d 
All VTEs (n=256)      
Normal 702 66 9.4 (7.4-13.2) Reference Reference Reference 
COPD 333 57 17.1 (13.2-22.2) 1.97 (1.36-2.84) 1.96 (1.35-2.84) 2.00 (1.30-3.08) 
Pulmonary embolism (n=130)     
Normal 329 34 10.3 (7.4-14.5) Reference Reference Reference 
COPD 172 27 15.7 (10.8-22.9) 1.48 (0.86-2.56) 1.48 (0.86-2.56) 1.45 (0.73-2.86) 
Deep vein thrombosis (n=126)     
Normal 374 32 8.6 (6.05-12.1) Reference Reference Reference 
COPD 161 30 18.7 (13.1-26.7) 2.51 (1.48-4.26) 2.65 (1.55-4.51) 2.28 (1.19-4.40) 
a Per 100 person-years  
b Adjusted for age (as timescale) and sex 
c Adjusted for age (as timescale), sex and physical activity 




Table 3. Mortality rates (MR) and Hazard ratio (HR) with 95% confidence intervals (CI) of death in patients with a first venous thromboembolism (VTE) 
according to stages of chronic obstructive pulmonary disease (COPD). 
 
 Person- years Deaths MR 
 (95% CI)a HR  (95% CI) b HR  (95% CI)c HR  (95% CI)d 
All VTEs (n=256)      
Normal 702 66 9.4 (7.4-12.0) Reference Reference Reference 
Stage I 141 15 10.6 (6.4-17.6) 1.22 (0.69-2.15) 1.23 (0.70-2.18) 1.18 (0.63-2.21) 
Stage II 161 27 16.7 (11.5-24.4) 1.94 (1.21-3.12) 1.90 (1.18-3.04) 2.23 (1.30-3.85) 
Stage III/IV 30 15 50.7 (30.6-84.1) 5.97 (3.29-10.82) 6.04 (3.33-10.9) 5.20 (2.65-10.2) 
Pulmonary embolism (n=130)     
Normal 329 34 10.4 (7.4-14.5) Reference Reference Reference 
Stage I 79 10 12.7 (6.8-23.5) 1.21 (0.58-2.55) 1.23 (0.59-2.57) 1.08 (0.46-2.51) 
Stage II 82 9 11.0 (5.7-21.1) 1.00 (0.45-2.22) 1.00 (0.45-2.23) 1.52 (0.57-4.03) 
Stage III/IV 11 8 72.6 (36.3-145) 7.48 (3.07-18.2) 7.91 (3.17-19.8) 7.39 (2.11-25.8) 
Deep vein thrombosis (n=126)     
Normal 374 32 8.6 (6.0-12.1) Reference Reference Reference 
Stage I 63 5 8.0 (3.3-19.1) 1.10 (0.42-2.88) 1.27 (0.48-3.37) 1.27 (0.42-3.82) 
Stage II 79 18 22.7 (14.3-36.0) 3.17 (1.69-5.96) 2.98 (1.59-5.60) 2.91 (1.27-6.64) 
Stage III/IV 19 7 37.7 (18.0-79.0) 4.69 (1.93-11.4) 5.72 (2.29-14.3) 3.74 (1.26-11.1) 
a Per 100 person-years  
b Adjusted for age (as timescale) and sex 
c Adjusted for age (as timescale), sex and physical activity 





Supplementary table 1. Mortality rates (MR) and Hazard ratio (HR) with 95% confidence intervals (CI) of death according to stages of chronic obstructive 
pulmonary disease (COPD) in patients with and without cancer-related venous thromboembolism (VTE). 
 
 Person- years Deaths MR 
 (95% CI)a HR  (95% CI) b HR  (95% CI)c HR  (95% CI)d 
No cancer (n=175)      
Normal 607 25 4.1 (2.8-6.1) Reference Reference Reference 
Stage I 133 8 6.0 (3.0-12.0) 1.48 (0.65-3.33) 1.48 (0.66-3.35) 1.09 (0.43-2.81) 
Stage II 140 15 10.8 (6.5-17.8) 2.61 (1.31-5.21) 2.53 (1.27-5.03) 2.51 (1.21-5.18) 
Stage III/IV 27 8 29.9 (15.0-59.8) 11.2 (4.63-27.2) 11.4 (4.71-27.5) 11.4 (3.40-38.2) 
Cancer (n=81)     
Normal 95 41 43.3 (31.9-58.8) Reference Reference Reference 
Stage I 9 7 75.3 (35.9-158) 1.22 (0.47-3.17) 1.15 (0.43-3.07) 0.80 (0.28-2.29) 
Stage II 22 12 55.0 (31.2-96.8) 1.45 (0.69-3.05) 1.49 (0.70-3.17) 1.56 (0.63-3.90) 
Stage III/IV 3 7 245 (117-514) 3.17 (1.15-8.75) 3.37 (1.18-9.61) 4.67 (1.45-15.0) 
 
